Novo Nordisk's Semaglutide Shows Remarkable Results In Study
Zacks Investment Research | Aug 17, 2017 06:26AM ET
Novo Nordisk (CO:NOVOb) (NYSE:NVO) announced results from SUSTAIN 7 study, which showed that people with type II diabetes who are treated with once-weekly semaglutide experienced superior reduction in HbA1c and body weight compared with treatment with Eli Lilly and Co's (NYSE:LLY) Trulicity (dulaglutide). when added to metformin.
In fact, semaglutide is a glucagon-like peptide-1 (GLP-1) analogue being evaluated for the treatment of adults with type II diabetes. Currently, it is under review by seven regulatory agencies, including the FDA, the European Medicines Agency, and the Japanese Pharmaceuticals and Medical Devices Agency.
Shares of the company have rallied 27.1% compared with the Zacks classified industry’s gain of 11.2% on a year-to-date basis.
Notably, the 40-week study evaluated the efficacy and safety of two dosages of semaglutide, in addition to initial standard-of-care therapy metformin against dulaglutide plus metformin. While 0.5 mg semaglutide was compared with 0.75 dulaglutide, 1.0 mg semaglutide was compared with 1.5 mg dulaglutide, when added to metformin.
The study presented that both the doses of semaglutide are statistically significant, and results in superior reduction of HbA1c. In addition, it showed people treated with both the doses of semaglutide experienced a statistically significant and superior weight loss at both doses.
Meanwhile, the superior glucose control and weight loss achieved with semaglutide compared to dulaglutide were consistent with the entire SUSTAIN program. In fact, the results revealed the potential of semaglutide to set a new standard for treatment of type II diabetes.
Novo Nordisk has a strong pipeline, primarily focusing on therapeutic proteins within insulin, GLP-1, blood clotting factors and human growth hormone. The company is making efforts to develop new treatments for diabetes, which is its core area of expertise. Key pipeline candidates include semaglutide and nonacog beta pegol. The potential approval of these candidates will boost the company’s top line.
Zacks Rank & Stocks to Consider
Novo Nordisk currently holds a Zacks Rank #3 (Hold). Better-ranked stocks in health care sector include Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) . Both Alexion and Regeneron sport a Zacks Rank #1 (Strong Buy). You can see .
Get The News You Want
Alexion Pharmaceuticals’ earnings per share estimates have moved up from $4.55 to $4.77 for 2017 and from $5.49 to $6.43 for 2018 over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 12.26%. The share price of the company has increased 11.7% year to date.
Regeneron’s earnings per share estimates have increased from $10.52 to $13.81 for 2017 and from $12.10 to $14.54 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.29%. The share price of the company has increased 27.6% year to date.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing and exclusive of fees, it can turn thousands into millions of dollars. This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.